El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
BioNTech SE ADR
Cerrado
SectorSalud
100.91 -0.96
Resumen
Variación precio
24h
Mínimo
98.6
Máximo
101.92
Ingresos | 369M -34M |
|---|---|
Ventas | 1.3B 1.5B |
Margen de beneficio | -2.208 |
Empleados | 6,772 |
EBITDA | 498M 149M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +37.76% upside |
Próximas Ganancias | 10 mar 2026 |
|---|
Capitalización de Mercado | 2B 27B |
|---|---|
Apertura anterior | 101.87 |
Cierre anterior | 100.91 |
Noticias sobre sentimiento de mercado
By Acuity
100%
0%
336 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
BioNTech SE ADR Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
BioNTech SE ADR Esperado
Precio Objetivo
By TipRanks
37.76% repunte
Estimación a 12 meses
Media 143 USD 37.76%
Máximo 181 USD
Mínimo 113 USD
De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioNTech SE ADR Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de BioNTech SE ADR
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
Live chat